Histone modification is known to be associated with multidrug resistance phenotypes.
Cancer cell lines that are resistant or have been made resistant to anti-
cancer drugs showed lower expression levels of
histone deacetylase-3 (HDAC3), among the
histone deacetylase(s), than
cancer cell lines that were sensitive to anti-
cancer drugs.
Celastrol and
Taxol decreased the expression of HDAC3 in
cancer cell lines sensitive to anti-
cancer drugs. HDAC3 negatively regulated the invasion, migration, and anchorage-independent growth of
cancer cells. HDAC3 conferred sensitivity to anti-
cancer drugs in vitro and in vivo. TargetScan analysis predicted miR-326 as a negative regulator of HDAC3. ChIP assays and
luciferase assays showed a negative feedback loop between HDAC3 and miR-326. miR-326 decreased the apoptotic effect of anti-
cancer drugs, and the miR-326 inhibitor increased the apoptotic effect of anti-
cancer drugs. miR-326 enhanced the invasion and migration potential of
cancer cells. The miR-326 inhibitor negatively regulated the tumorigenic, metastatic, and angiogenic potential of anti-
cancer drug-resistant
cancer cells. HDAC3 showed a positive feedback loop with
miRNAs such as miR-200b, miR-217, and miR-335. miR-200b, miR-217, and miR-335 negatively regulated the expression of miR-326 and the invasion and migration potential of
cancer cells while enhancing the apoptotic effect of anti-
cancer drugs. TargetScan analysis predicted miR-200b and miR-217 as negative regulators of
cancer-associated gene, a
cancer/testis antigen, which is known to regulate the response to anti-
cancer drugs. HDAC3 and miR-326 acted upstream of the
cancer-associated gene. Thus, we show that the miR-326-HDAC3 feedback loop can be employed as a target for the development of anti-
cancer therapeutics.